Tildrakizumab clinical trials
Also written MK-3222 and Ilumya.
How each study uses tildrakizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the tildrakizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 20 Mar 2018 · ILUMYA · BLA 761067 (FDA, Drugs@FDA)
- European Union
- 17 Sept 2018 · Ilumetri · EMEA/H/C/004514 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
20 studies that test it; most in 2020 (9)
| Year | Studies |
|---|---|
| 2010 | 1 |
| 2012 | 1 |
| 2013 | 2 |
| 2018 | 1 |
| 2019 | 1 |
| 2020 | 9 |
| 2021 | 2 |
| 2022 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 9
Sun Pharmaceutical Industries Limited (7) · University of California, San Francisco (2) · Almirall, S.A. (2) · Radboud University Medical Center (1) · Marcelo F. Di Carli, MD, FACC (1) · Medical College of Wisconsin (1) · Premier Specialists, Australia (1) · Carlos Wambier (1)
Often tested with
Tested in the same studies.
Secukinumab (2) · Ixekizumab (2) · Guselkumab (2) · Risankizumab (2) · Bimekizumab (2) · Brodalumab (1) · Triamcinolone (1) · Fluorouracil (1)
Studies
Open first, then newest update. How each study uses tildrakizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 20
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as TildrakizumabHow we know
- ILUMYA in Combination With HALOG Ointment 0.1% for Plaque Psoriasis.RecruitingPhase 4Psoriasis Treatment Center of Central New JerseyNCT04347473Written as Ilumya Injectable ProductHow we know
- A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous Tildrakizumab (SCH 900222/MK-3222) in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Followed by a Long-term Extension Study (MK-3222-011)CompletedPhase 3Sun Pharmaceutical Industries LimitedNCT01729754Written as Tildrakizumab 200 mgHow we know
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis.Active, not recruitingPhase 3Sun Pharmaceutical Industries LimitedNCT06611163Written as Tildrakizumab 100 mgHow we know
- A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque PsoriasisActive, not recruitingPhase 2/3Sun Pharmaceutical Industries LimitedNCT03997786Written as TildrakizumabHow we know
- Efficacy and Safety Study of Tildrakizumab in the Treatment of Nail PsoriasisCompletedPhase 3Sun Pharmaceutical Industries LimitedNCT03897075Written as TildrakizumabHow we know
- Dose Reduction of IL17 and IL23 Inhibitors in PsoriasisCompletedPhase 4Radboud University Medical CenterNCT04340076Written as TildrakizumabHow we know
- MIcrovascular dysfuNction In Moderate-severe PsoriasisCompletedPhase 4Marcelo F. Di Carli, MD, FACCNCT04271540Written as TildrakizumabHow we know
- Tildrakizumab for Prevention of Acute Graft-Versus-Host DiseaseCompletedPhase 2Medical College of WisconsinNCT04112810Written as TildrakizumabHow we know
- Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.CompletedPhase 2/3Sun Pharmaceutical Industries LimitedNCT03552276Written as SUNPG18_07 I (Tildrakizumab 200 mg)How we know
- Pilot Study Assessing the Effect of Tildrakizumab in VitiligoCompletedEarly Phase 1Premier Specialists, AustraliaNCT04971200Written as TildrakizumabHow we know
- Effects of Tildrakizumab on Epigenetic AgeCompletedPhase 4Carlos WambierNCT05110313Written as TILDRAKIZUMABHow we know
- Predicting Inflammatory Skin Disease Response to IL-23 BlockadeCompletedPhase 4University of California, San FranciscoNCT04541329Written as TildrakizumabHow we know
- Abiraterone Acetate in Combination With TildrakizumabTerminatedPhase 1/2Institute of Cancer Research, United KingdomNCT04458311Written as TildrakizumabHow we know
- A Phase Ⅲ Study to Evaluate Tildrakizumab in the Treatment of Chinese Subjects With Moderate to Severe Plaquetype PsoriasisCompletedPhase 3Shenzhen Kangzhe Pharmaceutical Co., Ltd.NCT05108766Written as Tildrakizumab 100 mgHow we know
- Efficacy and Safety of Tildrakizumab 100 Milligrams (mg) in Participants With Moderate-Severe Chronic Plaque Psoriasis and Its Impact on Their Quality of Life (TRIBUTE)CompletedPhase 4Almirall, S.A.NCT04229836Written as Tildrakizumab 100 mg Solution for InjectionHow we know
- A Study to Evaluate the Efficacy and Safety of Subcutaneous MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-010)CompletedPhase 3Sun Pharmaceutical Industries LimitedNCT01722331Written as Tildrakizumab 200 mgHow we know
- A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)WithdrawnPhase 3Sun Pharmaceutical Industries LimitedNCT01936688Written as MK-3222 200 mgHow we know
- Long-Term Treatment Effect With Tildrakizumab in Participants With Plaque PsoriasisTerminatedPhase 4Almirall, S.A.NCT04339595Written as TildrakizumabHow we know
- A Study to Determine the Optimal Dose of Tildrakizumab (SCH 900222/MK-3222) for the Treatment of Moderate-to-severe Chronic Plaque Psoriasis (P05495) (MK-3222-003)CompletedPhase 2Merck Sharp & Dohme LLCNCT01225731Written as tildrakizumabHow we know
Given beside what is tested · 1 — tildrakizumab is usual care or a partner of the new treatment
Codes
What other systems call tildrakizumab · ClinicalTrials.gg INT000235
- MeSH (NLM) C000598434tildrakizumabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) DEW6X41BEKTILDRAKIZUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2053436Confirmed FDA, Wikidata
- Wikidata Q15708331tildrakizumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152627TildrakizumabOne source FDA
- DrugBank DB14004One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000598434 | tildrakizumab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | DEW6X41BEK | TILDRAKIZUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2053436 | — | Confirmed FDA, Wikidata |
| Wikidata | Q15708331 | tildrakizumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152627 | Tildrakizumab | One source FDA |
| DrugBank | DB14004 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.